Published in Cancer Weekly, July 28th, 1997
The company also announced that it has initiated a Phase II efficacy trial with Onyx-015 in that same indication and is planning to start Phase II testing of the virus in combination with chemotherapy.
In a presentation made at the Montgomery Securities Healthcare Conference, held in New York, Hollings C. Renton, Onyx, said that treatment with Onyx-015 was well-tolerated by all of the 32 patients completing the trial, and investigators observed no...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.